Novo Nordisk executive reports high interest for once-daily, oral weight-loss pill
Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday. Wegovy’s once-daily pill, an oral spin-off of its injectable weight loss medication, was approved in December 2025 by the Food and Drug Administration as the first oral GLP-1 drug and launched on U.S. […]
The launch of the world’s first weight-loss pill
Bad news for all those who have been trying to make “Jabuary” a thing, said Angus Colwell in The Spectator. The launch of the world’s first weight-loss pill – which has gone on sale in the US at a fraction of the cost of injectable versions – has rather stolen their thunder. Patients used to […]
Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
This review talks about the development of incretin agonists (glucagon-like peptide-1 [GLP-1], GIP [glucose-dependent insulinotropic polypeptide], glucagon), oral formulation development approaches, and advanced drug delivery platforms. It provides details about clinical trials on incretin agonists, focussing on efficacy, safety, and innovations in clinical research. ABSTRACT Incretin-based therapies have become central to type 2 diabetes (T2D) […]
Ongoing lymphoid HIV production drives pyroptosis and GLP-1 counter-regulation in ART-suppressed infection
Despite effective antiretroviral therapy (ART), many people with HIV (PWH) exhibit persistent immune activation (IA) and suffer metabolic comorbidities. We investigated whether residual HIV production in lymphoid tissues drives IA. Among 20 ART-suppressed PWH, HIV RNA+ cells were detected in lymph nodes and correlated directly with markers of pyroptosis, assessed via cleaved gasdermin D positivity, […]
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced on January 8 the selection of AMX0318 as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist and was identified through a research collaboration with […]
The clock starts ticking the day you quit your GLP‑1 medication – Scripps News
The clock starts ticking the day you quit your GLP‑1 medication Scripps News People coming off weight-loss injections risk fast weight gain BBC Many people who come off GLP-1 drugs regain weight within 2 years, review suggests CNN Former GLP-1 users regain lost weight after about 18 months, study says The Washington Post Less than two years after stopping […]
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
Quick Read Lilly posted 53.9% revenue growth and 480% net income growth driven by GLP-1 drugs Mounjaro and Zepbound. Lilly’s operating margin hit 48.3% versus J&J’s 30.2%. Gross margin reached 82.9%. Novo Nordisk’s oral Wegovy approval in December 2025 introduces new competition to Lilly’s injectable GLP-1 franchise. It sounds nuts, but SoFi is giving new active […]
People Who Go Off GLP-1s Are Experiencing a Sudden and Terrible Hunger
Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, like the popular weight-loss jabs Wegovy and Ozempic, have proven to be immensely effective. Beyond allowing patients to significantly reduce their weight, they’ve been shown to have a constellation of other health benefits, like lowering the risk of heart disease and staving off diabetic kidney disease, Parkinson’s, and Alzheimer’s. […]
Medicina, Vol. 62, Pages 143: GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study
Medicina, Vol. 62, Pages 143: GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study Medicina doi: 10.3390/medicina62010143 Authors: Musa Salmanoglu Gulcin Ercan Hanife Seyda Genç Serdar Savaş Gül Hatice Aygün Background and Objectives: This study was designed to evaluate the potential cardioprotective effect of Exenatide […]